Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

Describe new treatment options available for polymyalgia rheumatica
Recommend new treatment options available for gout
Improve diagnostic acumen for rare autoimmune diseases such as VEXUS
Employ the new recommendations for treating CTD-ILD
Improve patient outcomes with treatment guidelines for ANCA vasculitis

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Rovin, Brad H., et al. "Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial." Arthritis & Rheumatology (2023).
Schett G, Munoz L, Taubmann J, Aigner M, Bergmann C, Knitza J, Kroenke G, Werner D, Müller F, Mackensen A. CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).
Beck, David B., et al. "Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population." JAMA 329.4 (2023): 318-324.
Goodman, Susan M., et al. "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty." The Journal of Arthroplasty 37.9 (2022): 1676-1683.

Joint Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credits™.Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:

Jeremy Tilstra, MD, PhD — Assistant Professor of Medicine, Division of Rheumatology, University of Pittsburgh School of Medicine
Dr. Tilstra is a consultant for Souffle Therapeutics.

Robin Domsic, MD, MPH — Associate Professor of Medicine, Division of Rheumatology, University of Pittsburgh School of Medicine
Dr. Domsic is a consultant for Aisa Pharmaceuticals and AstraZeneca.

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.